EGFR and non-small cell lung carcinoma: In September 2021, the FDA accelerated the approval of mobocertinib for the treatment of locally advanced or metastatic NSCLC patients with EGFR ex20ins mutations confirmed by FDA approved testing methods during or after platinum chemotherapy.